Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
GOSS•FDA filing for seralutinib
Sept. 24 (Reuters) - Gossamer Bio, Inc. GOSS.O:
- Gossamer Bio submits new drug application to U.S. FDA for seralutinib for the treatment of pulmonary arterial hypertension.
- Gossamer Bio said the FDA will determine NDA acceptance for filing later this year.
